Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study

Ahn, Myung JMyung JAhnKim, Hye RHye RKimCHIH-HSIN YANGHan, Ji-YuJi-YuHanLi, Jacky Yu-ChungJacky Yu-ChungLiHochmair, Maximilian JMaximilian JHochmairChang, Gee-ChenGee-ChenChangDelmonte, AngeloAngeloDelmonteLee, Ki HKi HLeeCampelo, Rosario GRosario GCampeloGridelli, CesareCesareGridelliSpira, Alexander IAlexander ISpiraCalifano, RaffaeleRaffaeleCalifanoGriesinger, FrankFrankGriesingerGhosh, SharmisthaSharmisthaGhoshFelip, EnriquetaEnriquetaFelipKim, Dong-WanDong-WanKimLiu, YuyinYuyinLiuZhang, PingkuanPingkuanZhangPopat, SanjaySanjayPopatCamidge, D RossD RossCamidge2023-03-022023-03-022022-121525-7304https://scholars.lib.ntu.edu.tw/handle/123456789/628841Brigatinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor with demonstrated efficacy in locally advanced and metastatic non-small cell lung cancer (NSCLC) in crizotinib-refractory and ALK inhibitor-naive settings. This analysis assessed brigatinib in Asian vs. non-Asian patients from the first-line ALTA-1L trial.enALK TKI-naive; Anaplastic lymphoma kinase; Clinical trial; First line; Tyrosine kinase inhibitor[SDGs]SDG3Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Studyjournal article10.1016/j.cllc.2022.07.008360384162-s2.0-85136735466WOS:000905581000019https://api.elsevier.com/content/abstract/scopus_id/85136735466